Momenta Pharmaceuticals, Inc. is a leader in applying breakthroughs in understanding the chemistry and biology of complex sugars to the discovery, development, and commercialization of drug products. In its short history, Momenta has built a diversified pipeline of product candidates comprised of novel therapeutics and the application of its technology to existing products and molecules. Complex sugars play a fundamental role in most basic cellular functions in addition to serving as modulators of the activity of critical proteins. While scientists have long recognized that sugars are important, efforts to decipher the specific roles that sugars play in promoting or treating human diseases have been impeded by the lack of technology capable of deciphering the incredible information density contained in sugar molecules. Momenta’s proprietary technology provides a more complete understanding of disease and drug action by enabling, for the first time, high throughput sequencing, precise chemical structure characterization, and engineering of complex sugars and glycosylated biomolecules. Momenta leverages this insight to develop novel therapeutics, make improvements to existing drugs, and discover new biological processes and pathways. Momenta’s areas of focus include cardiovascular disease, oncology, glycoprotein analysis and engineering, and non-invasive drug delivery. Founded in 2001, Momenta is headquartered in Cambridge, MA.